Evaluation of the FARAFLEX Mapping and Pulsed Field Ablation System in Subjects With Atrial Fibrillation - A Global Prospective Single Arm Study
The goal of this clinical trial is to learn if the FARAFLEX™ Mapping and pulsed field ablation (PFA) System can safely and effectively treat symptomatic, drug-refractory Paroxysmal atrial fibrillation (PAF) and Persistent atrial fibrillation (PersAF). The main question it aims to answer is: Is the FARAFLEX Mapping and PFA System a safe and effective treatment for patients? Participants will undergo an ablation procedure using the FARAFLEX Mapping and PFA System.
• At least 18 years old (or older if required by local law)
• Symptomatic, documented, drug-refractory paroxysmal or persistent atrial fibrillation (AF).
• Willing and capable of providing written informed consent
• Willing and able to comply with all follow-up assessments and study procedures at an approved investigational site